These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16262900)

  • 1. Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration.
    Pullamsetti S; Krick S; Yilmaz H; Ghofrani HA; Schudt C; Weissmann N; Fuchs B; Seeger W; Grimminger F; Schermuly RT
    Respir Res; 2005 Nov; 6(1):128. PubMed ID: 16262900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
    Schermuly RT; Kreisselmeier KP; Ghofrani HA; Samidurai A; Pullamsetti S; Weissmann N; Schudt C; Ermert L; Seeger W; Grimminger F
    Circ Res; 2004 Apr; 94(8):1101-8. PubMed ID: 15031263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension.
    Schermuly RT; Yilmaz H; Ghofrani HA; Woyda K; Pullamsetti S; Schulz A; Gessler T; Dumitrascu R; Weissmann N; Grimminger F; Seeger W
    Am J Respir Crit Care Med; 2005 Aug; 172(3):358-63. PubMed ID: 15879421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
    Cheng G; Wang X; Li Y; He L
    Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases.
    Pullamsetti SS; Savai R; Schaefer MB; Wilhelm J; Ghofrani HA; Weissmann N; Schudt C; Fleming I; Mayer K; Leiper J; Seeger W; Grimminger F; Schermuly RT
    Circulation; 2011 Mar; 123(11):1194-204. PubMed ID: 21382892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis.
    McMurtry MS; Bonnet S; Wu X; Dyck JR; Haromy A; Hashimoto K; Michelakis ED
    Circ Res; 2004 Oct; 95(8):830-40. PubMed ID: 15375007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin/NFAT Signaling Modulates Pulmonary Artery Smooth Muscle Cell Proliferation, Migration and Apoptosis in Monocrotaline-Induced Pulmonary Arterial Hypertension Rats.
    He RL; Wu ZJ; Liu XR; Gui LX; Wang RX; Lin MJ
    Cell Physiol Biochem; 2018; 49(1):172-189. PubMed ID: 30134231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Icotinib Attenuates Monocrotaline-Induced Pulmonary Hypertension by Preventing Pulmonary Arterial Smooth Muscle Cell Dysfunction.
    Peng LY; Yu M; Yang MX; Liu P; Zhou H; Huang W; Kong H; Xie WP
    Am J Hypertens; 2020 Aug; 33(8):775-783. PubMed ID: 32301965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.
    Hadri L; Kratlian RG; Benard L; Maron BA; Dorfmüller P; Ladage D; Guignabert C; Ishikawa K; Aguero J; Ibanez B; Turnbull IC; Kohlbrenner E; Liang L; Zsebo K; Humbert M; Hulot JS; Kawase Y; Hajjar RJ; Leopold JA
    Circulation; 2013 Jul; 128(5):512-23. PubMed ID: 23804254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effects of the ATP-sensitive potassium channel opener pinacidil and simvastatin on pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension.
    Jiang L; Zhou T; Liu H
    Pharmazie; 2012 Jun; 67(6):547-52. PubMed ID: 22822545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition.
    Dony E; Lai YJ; Dumitrascu R; Pullamsetti SS; Savai R; Ghofrani HA; Weissmann N; Schudt C; Flockerzi D; Seeger W; Grimminger F; Schermuly RT
    Eur Respir J; 2008 Mar; 31(3):599-610. PubMed ID: 18032446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhalation of the BK(Ca)-opener NS1619 attenuates right ventricular pressure and improves oxygenation in the rat monocrotaline model of pulmonary hypertension.
    Revermann M; Neofitidou S; Kirschning T; Schloss M; Brandes RP; Hofstetter C
    PLoS One; 2014; 9(1):e86636. PubMed ID: 24497961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.
    Cheng Y; Yu M; Xu J; He M; Wang H; Kong H; Xie W
    BMC Pulm Med; 2018 Aug; 18(1):130. PubMed ID: 30086741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.
    Comeglio P; Filippi S; Sarchielli E; Morelli A; Cellai I; Corno C; Adorini L; Vannelli GB; Maggi M; Vignozzi L
    J Endocrinol Invest; 2019 Aug; 42(8):951-965. PubMed ID: 30674010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced, pulmonary vascular remodeling in rats.
    Horstman DJ; Frank DU; Rich GF
    Anesth Analg; 1998 Jan; 86(1):74-81. PubMed ID: 9428855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
    Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
    J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
    Schermuly RT; Ghofrani HA; Enke B; Weissmann N; Grimminger F; Seeger W; Schudt C; Walmrath D
    Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1500-6. PubMed ID: 10556112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel PDGFR inhibitor WQ-C-401 prevents pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension.
    Huang W; Zhou H; He Y; Wang A; Wang B; Chen Y; Liu C; Wang H; Xie W; Kong H
    Exp Cell Res; 2024 Aug; 441(1):114154. PubMed ID: 38996959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
    Long L; Crosby A; Yang X; Southwood M; Upton PD; Kim DK; Morrell NW
    Circulation; 2009 Feb; 119(4):566-76. PubMed ID: 19153267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.